Rehmann Capital Advisory Group’s Emergent Biosolutions EBS Stock Holding History

Rehmann Capital Advisory Group’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$56.5K	Buy	1,081 +47	+5%	+$2.19K	0.01%	583
2019 Q2	$50K	Buy	1,034 +778	+304%	+$37.3K	0.01%	835
2019 Q1	$12.9K	Sell	256 -196	-43%	-$11.6K	﹤0.01%	1251
2018 Q4	$26.8K	Buy	452 +199	+79%	+$12.8K	﹤0.01%	784
2018 Q3	$16.7K	Buy	253 +15	+6%	+$875	﹤0.01%	1180
2018 Q2	$12K	Sell	238 -18	-7%	-$938	﹤0.01%	1276
2018 Q1	$13K	Buy	+256	New	+$12.8K	﹤0.01%	1212

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Rehmann Capital Advisory Group's EBS Position: Q3 2019 in Review

Rehmann Capital Advisory Group increased its Emergent Biosolutions (EBS) stake by 4.5% in Q3 2019, buying an estimated $2.19K and bringing the position to 1,081 shares worth $56.5K. The position accounts for 0.01% of the portfolio, ranked #583.

Rehmann Capital Advisory Group first reported a position in EBS in Q1 2018 and has held it in 7 quarters since. 244 funds tracked by Wall St. Rank hold EBS as of Q3 2019.

Rehmann Capital Advisory Group held 1,081 shares of Emergent Biosolutions worth $56.5K as of Q3 2019.
Rehmann Capital Advisory Group bought 47 Emergent Biosolutions shares in Q3 2019, an estimated $2.19K.
Emergent Biosolutions made up 0.01% of Rehmann Capital Advisory Group's portfolio in Q3 2019, its #583 holding.
Rehmann Capital Advisory Group first reported a position in Emergent Biosolutions in Q1 2018 and has held it in 7 quarters since.
244 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.